Collaborative Engagements

The Seafood Traceability Phase 1 Progress Report highlights the need for full-chain, digital and interoperable traceability in today’s complex and global supply chains. In the first year of this engagement, delivered in partnership with WWF US, Planet Tracker, the World Benchmarking Alliance and UNEP FI, we have assessed seven of the largest seafood producers on their traceability efforts.

Explore the latest report, which assesses how 20 of the largest food retailers and manufacturers are diversifying their protein portfolios as a means to reduce the material risks associated with animal protein production and seize new market opportunities.

Explore the latest report, which focuses on the progress made by companies in the second phase of this engagement, as well as areas where there remain significant gaps with leading practices.

In May 2023, FAIRR launched two engagements; Animal Pharmaceuticals (Phase 2) and Restaurant Antibiotics (Phase 1). The engagements aim to improve transparency around how companies operating at different stages of the protein value chain are working to ensure responsible antibiotic use at the farm level.   

The report highlights key findings, provides company-specific examples, and explains how companies could improve disclosure to demonstrate that they are addressing the systemic risk of AMR. 

FAIRR is pleased to launch the third phase of its Sustainable Aquaculture engagement, taking a deep dive on biodiversity risks in farmed salmon feed sourcing. The salmon industry’s reliance on wild-caught fish and a lack of feed traceability are key issues of concern. Therefore, this engagement aims to push large salmon producers to conduct meaningful risk assessments in line with the TNFD, as well as to adopt a timely target and associated strategy to reduce their exposure to forage fish used in their feed.

The overconsumption of animal protein in Western geographies is leading to adverse impacts on climate, nature, and human health. FAIRR’s new insight piece explores how transitioning to the consumption of plant-based proteins can address these three impacts.

FAIRR’s third progress update on the Working Conditions engagement provides in-depth analysis on the performance of six global meat producers across a range of material labour risk factors and explores key industry trends. The engagement focuses on raising worker voice in corporate structures through three key themes: health and safety, fair working conditions, and worker representation. 

Following six successful years of engaging companies on the need to diversify their protein portfolio, FAIRR has closed its Sustainable Proteins engagement. Building on key learnings, integrating the latest scientific guidance, and acknowledging market changes, FAIRR is pleased to launch its Protein Diversification engagement with 20 global food manufacturers and retailers.

In September 2022, FAIRR launched a first-of-its-kind collaborative investor engagement aiming to drive ten global pork and poultry producers to conduct meaningful risk assessments around their management of manure and animal waste and to put in place action plans that reduce their impact on biodiversity. The Phase 1 Progress Report discusses how these companies assess the risks driven by the pollution across their value chains and also offers investors best practice examples. The report includes suggestions for follow-up engagement questions, a discussion of the potential opportunities of nutrient circularity, as well as granular data on the performance of companies against the assessment framework.

This webinar explored the key takeaways from the first dialogues of our biodiversity, Waste & Pollution Collaborative Engagement. It also offered members a preview of FAIRR's upcoming work on regenerative agriculture and biodiversity-wide scenario analysis.

In May 2022, FAIRR launched a collaborative investor engagement focused on 7 global publicly-listed animal pharmaceutical companies and is supported by 65 investors representing over $17 trillion in combined assets. The aim is to drive greater disclosure and clarity over how – and if – animal pharmaceutical companies are addressing the risk of AMR throughout their value chains, from factory to farm.

To view the progress achieved in the last year, download our latest report which discusses company efforts across manufacturing, labelling, marketing and sales practices.